**References Seminar ‘Stem Cell Transplantation: GVHD’**

Physiopathology

[Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy.](https://pubmed.ncbi.nlm.nih.gov/29171820/)

Zeiser R, Blazar BR.Zeiser R, et al. N Engl J Med. 2017 Nov 30;377(22):2167-2179. doi: 10.1056/NEJMra1609337.N Engl J Med. 2017. PMID: 29171820

[Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets.](https://pubmed.ncbi.nlm.nih.gov/29281578/)

Zeiser R, Blazar BR.Zeiser R, et al. N Engl J Med. 2017 Dec 28;377(26):2565-2579. doi: 10.1056/NEJMra1703472.N Engl J Med. 2017. PMID: 29281578

Diagnosis/Severity Scoring

[EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment.](https://pubmed.ncbi.nlm.nih.gov/29872128/)

Schoemans HM, Lee SJ, Ferrara JL, Wolff D, Levine JE, Schultz KR, Shaw BE, Flowers ME, Ruutu T, Greinix H, Holler E, Basak G, Duarte RF, Pavletic SZ; EBMT (European Society for Blood and Marrow Transplantation) Transplant Complications Working Party and the “EBMT−NIH (National Institutes of Health)−CIBMTR (Center for International Blood and Marrow Transplant Research) GvHD Task Force”.Schoemans HM, et al. Bone Marrow Transplant. 2018 Nov;53(11):1401-1415. doi: 10.1038/s41409-018-0204-7. Epub 2018 Jun 5.Bone Marrow Transplant. 2018. PMID: 29872128

[National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report.](https://pubmed.ncbi.nlm.nih.gov/33839317/)

Kitko CL, Pidala J, Schoemans HM, Lawitschka A, Flowers ME, Cowen EW, Tkaczyk E, Farhadfar N, Jain S, Steven P, Luo ZK, Ogawa Y, Stern M, Yanik GA, Cuvelier GDE, Cheng GS, Holtan SG, Schultz KR, Martin PJ, Lee SJ, Pavletic SZ, Wolff D, Paczesny S, Blazar BR, Sarantopoulos S, Socie G, Greinix H, Cutler C.Kitko CL, et al. Transplant Cell Ther. 2021 Jul;27(7):545-557. doi: 10.1016/j.jtct.2021.03.033. Epub 2021 Apr 9.Transplant Cell Ther. 2021. PMID: 33839317

[Nonclassical manifestations of acute GVHD.](https://pubmed.ncbi.nlm.nih.gov/34482399/)

Zeiser R, Teshima T.Zeiser R, et al. Blood. 2021 Dec 2;138(22):2165-2172. doi: 10.1182/blood.2021012431.Blood. 2021. PMID: 34482399

Treatment

[Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation.](https://pubmed.ncbi.nlm.nih.gov/32004485/)

Penack O, Marchetti M, Ruutu T, Aljurf M, Bacigalupo A, Bonifazi F, Ciceri F, Cornelissen J, Malladi R, Duarte RF, Giebel S, Greinix H, Holler E, Lawitschka A, Mielke S, Mohty M, Arat M, Nagler A, Passweg J, Schoemans H, Socié G, Solano C, Vrhovac R, Zeiser R, Kröger N, Basak GW.Penack O, et al. Lancet Haematol. 2020 Feb;7(2):e157-e167. doi: 10.1016/S2352-3026(19)30256-X.Lancet Haematol. 2020. PMID: 32004485

[Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease.](https://pubmed.ncbi.nlm.nih.gov/34260836/)

Zeiser R, Polverelli N, Ram R, Hashmi SK, Chakraverty R, Middeke JM, Musso M, Giebel S, Uzay A, Langmuir P, Hollaender N, Gowda M, Stefanelli T, Lee SJ, Teshima T, Locatelli F; REACH3 Investigators.Zeiser R, et al. N Engl J Med. 2021 Jul 15;385(3):228-238. doi: 10.1056/NEJMoa2033122.N Engl J Med. 2021. PMID: 34260836

[Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease.](https://pubmed.ncbi.nlm.nih.gov/32320566/)

Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, Szer J, Wagner EM, Zuckerman T, Mahuzier B, Xu J, Wilke C, Gandhi KK, Socié G; REACH2 Trial Group.Zeiser R, et al. N Engl J Med. 2020 May 7;382(19):1800-1810. doi: 10.1056/NEJMoa1917635. Epub 2020 Apr 22.N Engl J Med. 2020. PMID: 32320566

Interesting links

[www.uzleuven.be/egvhd](http://www.uzleuven.be/egvhd)

<https://www.ebmt.org/physicians-webinars>

<https://learn.astct.org/products/future-of-chronic-gvhd-2020-nih-chronic-gvhd-consensus-project-recommendations>

<https://learn.astct.org/products/diagnosing-and-assessing-chronic-graft-versus-host-disease?_zs=88RWl&_zl=PI092>

<https://learn.astct.org/products/principles-of-management-of-chronic-gvhd?_zs=88RWl&_zl=QI092>

<https://learn.astct.org/products/emerging-treatments-in-chronic-gvhd?_zs=88RWl&_zl=RI092>